Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib Alone and with Rituximab in Relapsed/Refractory B-Cell NHL
NCT01812005Phase 2Terminated
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- May 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in B-cell non-Hodgkin lymphoma, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started May 2013; status: terminated.
02
Drugs
alisertib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT01812005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812005.